Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model
- PMID: 8758907
Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model
Abstract
Recently, we demonstrated that an immunoglobulin-like cell adhesion molecule, C-CAM, acts as a tumor suppressor in prostate cancer. It is known that C-CAM is expressed in many epithelial cell types. In this study, we tested the possibility that C-CAM may also suppress bladder cancer progression. We used an orthotopic tumor model, which provides a relevant organ condition for examining the interaction between primary tumor cells and their microenvironment; this interaction has a critical impact on the behavior of carcinoma. We constructed a recombinant adenovirus expressing C-CAM1 (an isoform of C-CAM) and infected the 253J B-V cell line, a tumorigenic human bladder carcinoma subline. In vitro, C-CAM1 protein was detected in C-CAM1 adenovirus-infected cells but not in antisense control virus-infected cells, and the levels of expression showed dose dependency. When these cells were injected orthotopically in nude mice, we found that the increased expression of C-CAM1 in the 253J B-V cells repressed the growth of 253J B-V-induced tumors. Taken together, these data indicate that C-CAM1 is a potent tumor suppressor in human bladder cancer.
Similar articles
-
Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study.Cancer Res. 1995 Jul 1;55(13):2831-6. Cancer Res. 1995. PMID: 7796410
-
Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer.Semin Oncol. 1999 Apr;26(2):227-33. Semin Oncol. 1999. PMID: 10597733 Review.
-
Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches.Cancer Res. 1995 Jan 1;55(1):190-7. Cancer Res. 1995. PMID: 7805032
-
Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model.Anticancer Res. 1999 Jan-Feb;19(1A):337-40. Anticancer Res. 1999. PMID: 10226564
-
Human prostate cancer progression models and therapeutic intervention.Hinyokika Kiyo. 1997 Nov;43(11):815-20. Hinyokika Kiyo. 1997. PMID: 9436028 Review.
Cited by
-
The old CEACAMs find their new role in tumor immunotherapy.Invest New Drugs. 2020 Dec;38(6):1888-1898. doi: 10.1007/s10637-020-00955-w. Epub 2020 Jun 2. Invest New Drugs. 2020. PMID: 32488569 Review.
-
On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies.J Immunol Res. 2018 Oct 14;2018:7169081. doi: 10.1155/2018/7169081. eCollection 2018. J Immunol Res. 2018. PMID: 30406153 Free PMC article. Review.
-
Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients.Dis Markers. 2018 Jun 28;2018:6714287. doi: 10.1155/2018/6714287. eCollection 2018. Dis Markers. 2018. PMID: 30050594 Free PMC article.
-
CEACAM1 as a multi-purpose target for cancer immunotherapy.Oncoimmunology. 2017 May 16;6(7):e1328336. doi: 10.1080/2162402X.2017.1328336. eCollection 2017. Oncoimmunology. 2017. PMID: 28811966 Free PMC article. Review.
-
Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.Tumour Biol. 2014 Nov;35(11):10879-90. doi: 10.1007/s13277-014-2353-7. Epub 2014 Aug 2. Tumour Biol. 2014. PMID: 25085582
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical